Veracyte Free Cash Flow (FCF) History (VCYT)
Veracyte reported $126.6M in free cash flow for fiscal 2025, an increase of 98.45% from the previous fiscal year, with a free cash flow margin of 24.49%.
View full Veracyte company overviewVeracyte free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $126.6M | $62.8M | +98.45% | +24.49% |
| 2024 | 2024-12-31 | $63.8M | $29.5M | +86.24% | +14.31% |
| 2023 | 2023-12-31 | $34.3M | $35.3M | — | +9.49% |
| 2022 | 2022-12-31 | −$1.0M | $36.0M | — | −0.34% |
| 2021 | 2021-12-31 | −$37.0M | −$24.4M | — | −16.85% |
| 2020 | 2020-12-31 | −$12.5M | −$6.6M | — | −10.68% |
| 2019 | 2019-12-31 | −$6.0M | $9.4M | — | −4.97% |
| 2018 | 2018-12-31 | −$15.4M | $10.3M | — | −16.73% |
| 2017 | 2017-12-31 | −$25.7M | $6.5M | — | −35.68% |
| 2016 | 2016-12-31 | −$32.2M | $938,000 | — | −49.46% |
| 2015 | 2015-12-31 | −$33.1M | −$3.5M | — | −66.93% |
| 2014 | 2014-12-31 | −$29.7M | −$9.2M | — | −77.65% |
| 2013 | 2013-12-31 | −$20.5M | −$11.9M | — | −93.63% |
| 2012 | 2012-12-31 | −$8.6M | $5.2M | — | −74.21% |
| 2011 | 2011-12-31 | −$13.8M | — | — | −521.74% |
Veracyte quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $43.0M | $10.6M | +32.95% | +28.58% |
| Q1 2026 | 2026-03-31 | $32.3M | $28.7M | +810.33% | +23.19% |
| Q4 2025 | 2025-12-31 | $48.8M | $28.4M | +139.43% | +34.70% |
| Q3 2025 | 2025-09-30 | $42.0M | $14.2M | +51.38% | +31.82% |
| Q2 2025 | 2025-06-30 | $32.3M | $5.5M | +20.57% | +24.83% |
| Q1 2025 | 2025-03-31 | $3.5M | $14.6M | — | +3.10% |
| Q4 2024 | 2024-12-31 | $20.4M | $7.3M | +56.13% | +17.18% |
| Q3 2024 | 2024-09-30 | $27.7M | $16.4M | +143.83% | +23.93% |
| Q2 2024 | 2024-06-30 | $26.8M | $13.8M | +106.16% | +23.43% |
| Q1 2024 | 2024-03-31 | −$11.1M | −$7.9M | — | −11.46% |
| Q4 2023 | 2023-12-31 | $13.1M | $5.2M | +65.84% | +13.29% |
| Q3 2023 | 2023-09-30 | $11.4M | $6.1M | +114.02% | +12.62% |
| Q2 2023 | 2023-06-30 | $13.0M | $15.9M | — | +14.40% |
| Q1 2023 | 2023-03-31 | −$3.2M | $8.2M | — | −3.84% |
| Q4 2022 | 2022-12-31 | $7.9M | $267,000 | +3.51% | +9.80% |
| Q3 2022 | 2022-09-30 | $5.3M | $8.5M | — | +7.03% |
| Q2 2022 | 2022-06-30 | −$2.9M | −$3.2M | — | −3.94% |
| Q1 2022 | 2022-03-31 | −$11.3M | $30.4M | — | −16.71% |
| Q4 2021 | 2021-12-31 | $7.6M | $6.2M | +453.90% | +11.29% |
| Q3 2021 | 2021-09-30 | −$3.2M | −$4.3M | — | −5.31% |
| Q2 2021 | 2021-06-30 | $360,000 | $9.4M | — | +0.65% |
| Q1 2021 | 2021-03-31 | −$41.8M | −$35.8M | — | −113.77% |
| Q4 2020 | 2020-12-31 | $1.4M | $683,000 | +98.99% | +3.98% |
| Q3 2020 | 2020-09-30 | $1.1M | $2.9M | — | +3.59% |
| Q2 2020 | 2020-06-30 | −$9.1M | −$6.0M | — | −43.82% |
| Q1 2020 | 2020-03-31 | −$6.0M | −$4.2M | — | −19.17% |
| Q4 2019 | 2019-12-31 | $690,000 | $2.4M | — | +2.32% |
| Q3 2019 | 2019-09-30 | −$1.8M | $654,000 | — | −5.77% |
| Q2 2019 | 2019-06-30 | −$3.1M | $519,000 | — | −10.33% |
| Q1 2019 | 2019-03-31 | −$1.8M | $5.9M | — | −6.01% |
| Q4 2018 | 2018-12-31 | −$1.7M | $4.4M | — | −6.52% |
| Q3 2018 | 2018-09-30 | −$2.4M | $3.4M | — | −10.41% |
| Q2 2018 | 2018-06-30 | −$3.6M | $1.4M | — | −15.97% |
| Q1 2018 | 2018-03-31 | −$7.6M | $1.1M | — | −38.12% |
| Q4 2017 | 2017-12-31 | −$6.1M | −$1.4M | — | −31.21% |
| Q3 2017 | 2017-09-30 | −$5.8M | $1.8M | — | −33.28% |
| Q2 2017 | 2017-06-30 | −$5.0M | $3.4M | — | −27.29% |
| Q1 2017 | 2017-03-31 | −$8.7M | $2.8M | — | −52.95% |
| Q4 2016 | 2016-12-31 | −$4.7M | $2.3M | — | −25.64% |
| Q3 2016 | 2016-09-30 | −$7.6M | −$2.7M | — | −40.91% |
| Q2 2016 | 2016-06-30 | −$8.4M | $3.4M | — | −57.55% |
| Q1 2016 | 2016-03-31 | −$11.5M | −$2.1M | — | −84.52% |
| Q4 2015 | 2015-12-31 | −$7.0M | $1.9M | — | −49.99% |
| Q3 2015 | 2015-09-30 | −$4.9M | $2.2M | — | −39.93% |
| Q2 2015 | 2015-06-30 | −$11.8M | −$5.1M | — | −99.15% |
| Q1 2015 | 2015-03-31 | −$9.4M | −$2.5M | — | −83.60% |
| Q4 2014 | 2014-12-31 | −$9.0M | −$5.4M | — | −73.52% |
| Q3 2014 | 2014-09-30 | −$7.1M | −$1.8M | — | −72.36% |
| Q2 2014 | 2014-06-30 | −$6.7M | −$2.3M | — | −77.07% |
| Q1 2014 | 2014-03-31 | −$6.9M | $294,000 | — | −92.04% |
| Q4 2013 | 2013-12-31 | −$3.6M | — | — | −52.19% |
| Q3 2013 | 2013-09-30 | −$5.4M | — | — | −95.78% |
| Q2 2013 | 2013-06-30 | −$4.4M | — | — | −86.60% |
| Q1 2013 | 2013-03-31 | −$7.2M | — | — | −163.66% |
Veracyte free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$12.5M to $126.6M, a net increase of $139.2M. Veracyte's latest reported quarter, Q2 2026, generated $43.0M in free cash flow, an increase of 32.95% year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Veracyte filings at SEC.gov ↗